A diagnosis of advanced prostate cancer raises deeply difficult questions for patients and families. If you are searching for answers about how this disease progresses in its final stages — and what can be done about it — this guide explains the specific medical complications, organ impacts, and physical changes associated with advanced prostate cancer, along with current U.S. survival statistics and treatment options that may extend life and improve quality of care.
Prostate cancer is the most common cancer diagnosis among men in the United States, accounting for approximately 30% of male cancers in 2025. The American Cancer Society estimates 313,780 new cases and 35,770 deaths from prostate cancer in 2025 alone. While the overall 5-year relative survival rate is 98%, that number drops dramatically to 38% once the cancer has spread to distant organs — making understanding of disease progression critically important.
The Shift From Localized to Metastatic Cancer
To understand what causes death from prostate cancer, it helps to first understand how the disease behaves at different stages.
When prostate cancer first develops, it is typically confined entirely within the prostate gland. At this localized stage, the cancer is highly treatable and rarely life-threatening. The 5-year relative survival rate for localized prostate cancer is over 99%.
Death from prostate cancer occurs when the disease becomes metastatic — meaning cancer cells have broken away from the original tumor, traveled through the bloodstream or lymphatic system, and formed new tumors in other critical parts of the body. It is the damage to these other vital systems that ultimately causes mortality.
Prostate Cancer Survival Rates by Stage (U.S., SEER Database)
SEER Stage Description 5-Year Relative Survival Rate
Localized Cancer confined to the prostate >99%
Regional Spread to nearby structures or lymph nodes >99%
Distant Spread to bones, liver, lungs, or other distant organs 38%
All stages combined — 98%
Source: American Cancer Society / NCI SEER database, based on men diagnosed 2015–2021.
The good news: survival rates for men being diagnosed today may be higher than these numbers reflect, because treatments have improved significantly in recent years.
Bone Metastasis and Bone Marrow Failure
Prostate cancer has a very strong tendency to spread to the bones. The most common sites for these secondary tumors are the spine, pelvis, ribs, and upper leg bones (femur). Bone metastasis is present in approximately 85–90% of men who die from advanced prostate cancer, making it the single most common site of metastatic spread.
While bone tumors cause significant pain, they also trigger life-threatening systemic complications:
Bone Marrow Suppression
When cancer aggressively invades the bones, it infiltrates the bone marrow — the spongy tissue responsible for producing red blood cells, white blood cells, and platelets. As cancer cells crowd out healthy marrow, the body experiences severe bone marrow suppression:
Anemia — insufficient red blood cells mean organs don’t receive enough oxygen to function
Immune system collapse — without enough white blood cells, patients become highly vulnerable to infections; a secondary infection like pneumonia often becomes the actual immediate cause of death
Bleeding disorders — low platelet counts prevent normal blood clotting
Hypercalcemia
The rapid breakdown of bone tissue releases dangerously high levels of calcium into the bloodstream — a condition called hypercalcemia. Severe hypercalcemia can cause:
Kidney failure
Dangerous heart arrhythmias
Neurological symptoms (confusion, lethargy)
Eventually coma
Bone Metastasis Treatments
Several treatments can slow bone damage and reduce complications:
Treatment Type How It Helps
Radium-223 (Xofigo) Targeted radiation Delivers radiation directly to bone metastases; shown to improve survival
Denosumab (Xgeva) Monoclonal antibody Prevents bone breakdown and reduces fractures
Zoledronic acid (Zometa) Bisphosphonate Slows bone destruction from metastasis
External beam radiation Palliative radiation Relieves bone pain at specific metastatic sites
Urinary Tract Obstruction and Kidney Failure
Because the prostate gland wraps directly around the urethra (the tube that carries urine out of the body), a growing tumor can cause severe localized problems even before it spreads to distant organs.
A large prostate tumor can completely block the flow of urine from the bladder. If this obstruction is not relieved through medical intervention, urine backs up into the kidneys. This immense pressure damages the delicate filtration systems of the kidneys, leading to acute renal failure. When the kidneys fail, toxic waste products rapidly build up in the blood (uremia), which is fatal without dialysis.
Management options include:
Catheterization or stent placement to relieve obstruction
TURP (Transurethral Resection of the Prostate) to remove obstructing tumor tissue
Palliative radiation to shrink the tumor
Visceral Metastasis: Liver and Lung Impact
In the later stages of the disease, prostate cancer may spread to visceral organs — most commonly the liver and the lungs.
Liver Metastasis
When tumors grow in the liver, they destroy healthy tissue required to filter toxins, produce essential proteins, and aid digestion. As liver function declines, patients experience hepatic failure, leading to:
Buildup of toxins (jaundice, hepatic encephalopathy)
Impaired blood clotting
Multiple organ system shutdown
Lung Metastasis
If tumors spread extensively through the lungs, they block airways and destroy tissue needed for oxygen exchange. This leads to progressive respiratory failure, where the body cannot take in enough oxygen to sustain life. Patients may experience:
Shortness of breath (dyspnea)
Chronic cough
Increased risk of pneumonia (which can be the immediate cause of death)
Cancer Cachexia and Systemic Decline
Advanced cancer often triggers a complex metabolic syndrome known as cancer cachexia. This is not simply weight loss from a lack of appetite — it is a state where the body actively breaks down its own skeletal muscle and fat stores, driven by inflammatory chemicals (cytokines) released by the immune system and the tumor itself.
Patients with cachexia experience:
Extreme weakness and fatigue
Severe muscle wasting (sarcopenia)
Loss of appetite and early satiety
This severe physical decline eventually weakens the heart muscle and the muscles required for breathing, leading to cardiac arrest or respiratory failure. Cachexia affects an estimated 50–80% of advanced cancer patients and is considered a direct cause of death in approximately 20–30% of cancer fatalities.
Treatment Options for Advanced Prostate Cancer
One of the most important things to understand is that advanced prostate cancer is treatable — even when it is no longer curable. Modern treatments can extend life by years, manage symptoms, and preserve quality of life.
Hormone Therapy (Androgen Deprivation Therapy — ADT)
Because prostate cancer cells rely on testosterone to grow, suppressing male hormones is the backbone of advanced prostate cancer treatment:
Medication Class Notes
Leuprolide (Lupron) GnRH agonist Standard first-line hormone therapy
Degarelix (Firmagon) GnRH antagonist Immediate testosterone suppression
Abiraterone (Zytiga) CYP17 inhibitor Blocks androgen production everywhere in the body
Enzalutamide (Xtandi) Androgen receptor blocker Prevents testosterone from stimulating cancer cells
Apalutamide (Erleada) Androgen receptor blocker Used in non-metastatic castration-resistant disease
Darolutamide (Nubeqa) Androgen receptor blocker Newer agent with favorable side-effect profile
Chemotherapy
Medication Notes
Docetaxel (Taxotere) Standard first-line chemo for metastatic disease; often combined with ADT
Cabazitaxel (Jevtana) Used when docetaxel stops working
Targeted Therapy & Immunotherapy
Medication Type Use Case
Olaparib (Lynparza) PARP inhibitor For men with BRCA1/BRCA2 mutations
Rucaparib (Rubraca) PARP inhibitor For BRCA-mutated castration-resistant disease
Sipuleucel-T (Provenge) Immunotherapy Personalized immune treatment; extends survival in asymptomatic metastatic disease
Pembrolizumab (Keytruda) Immune checkpoint inhibitor For specific genetic profiles (MSI-H, dMMR)
Important: Treatment decisions depend on individual factors including cancer genetics, overall health, prior treatments, and personal preferences. This information is for educational purposes — always consult with a qualified oncologist.
U.S. Prostate Cancer Statistics & Racial Disparities
Understanding the scope of prostate cancer in the United States provides important context.
2025 U.S. Prostate Cancer Statistics (ACS)
Metric Number
New cases (2025 est.) 313,780
Deaths (2025 est.) 35,770
% of all male cancers ~30%
Rank among male cancer deaths 2nd (behind lung cancer)
Racial & Ethnic Disparities
Prostate cancer affects different communities at vastly different rates in the U.S.:
Population Mortality (per 100,000) Key Finding
Black men 36.9 2x mortality vs. White men; 67% higher incidence
American Indian / Alaska Native 20.6 Most likely to be diagnosed at distant stage (12% vs 8% White)
White men 18.4 Reference group
Hispanic men 15.4 —
Asian American / Pacific Islander 8.8 Lowest mortality rate
State-Level Mortality (Highest)
State Deaths per 100,000
Washington, D.C. 27.5
Mississippi 24.8
These states have high proportions of Black residents, reflecting the racial disparity in outcomes.
Screening Guidelines (ACS)
The American Cancer Society recommends:
All men: Discuss prostate cancer screening with a healthcare provider at age 50
Black men and those with a family history: Begin screening conversation at age 45
Screening typically involves a PSA blood test and may include a digital rectal exam (DRE)
Early detection is critical — when prostate cancer is caught at the localized stage, the 5-year survival rate exceeds 99%.
When to Seek Palliative Care
Palliative care is specialized medical care focused on providing relief from the symptoms and stress of a serious illness. It is not the same as hospice care — palliative care can be received at any stage of cancer treatment, alongside curative or life-prolonging therapies.
In advanced prostate cancer, palliative specialists work to:
Manage pain from bone metastasis (medications, radiation, nerve blocks)
Treat breathing difficulties from lung involvement
Address kidney function issues
Provide nutritional support for cachexia
Offer emotional and psychological support for patients and families
Coordinate care between oncologists, urologists, and primary care providers
The ACS recommends that patients with advanced cancer ask their oncologist about palliative care early in the treatment process — research shows that early palliative care improves both quality of life and, in some cases, survival.
For 24/7 support and information, the American Cancer Society helpline is available at 1-800-227-2345 or at cancer.org.
Frequently Asked Questions
Does localized prostate cancer cause death? No. If prostate cancer remains confined to the prostate gland, the 5-year relative survival rate is over 99%. Mortality is associated with the cancer spreading (metastasizing) to other vital organs — particularly bones, liver, and lungs — or causing severe local obstructions.
What is the most common site for prostate cancer to spread? The bones are by far the most common site, present in approximately 85–90% of men who die from advanced prostate cancer. The most frequent locations are the lower spine, pelvis, ribs, and femur (upper leg bone).
What is the 5-year survival rate for metastatic (distant) prostate cancer? According to the American Cancer Society and the NCI SEER database, the 5-year relative survival rate for distant-stage prostate cancer is approximately 38%. However, newer treatments (such as abiraterone, enzalutamide, and PARP inhibitors) may improve outcomes for men diagnosed today.
What actually causes death in advanced prostate cancer? The most common immediate causes of death include: bone marrow failure leading to infections (pneumonia), kidney failure from urinary obstruction or hypercalcemia, liver failure from visceral metastasis, respiratory failure from lung metastasis or cachexia-induced muscle weakness, and cardiac arrest from severe cachexia.
Are there treatments that can extend life with advanced prostate cancer? Yes. Modern treatments including hormone therapy (ADT), novel androgen blockers (abiraterone, enzalutamide), chemotherapy (docetaxel, cabazitaxel), immunotherapy (sipuleucel-T), and targeted therapy (PARP inhibitors for BRCA mutations) can extend survival by months to years while maintaining quality of life.
What is the role of palliative care in advanced prostate cancer? Palliative care focuses on relieving symptoms and improving quality of life. It is not limited to end-of-life care — it can be provided alongside curative or life-prolonging treatments. Palliative specialists manage bone pain, breathing difficulties, kidney issues, and provide emotional support.
Are certain groups of men at higher risk for prostate cancer death in the U.S.? Yes. Black men have approximately twice the mortality rate of White men and 67% higher incidence. The ACS recommends that Black men and those with a family history of prostate cancer begin screening conversations at age 45, five years earlier than the general recommendation of age 50.
How is prostate cancer screening done in the United States? Screening typically involves a PSA (prostate-specific antigen) blood test, sometimes combined with a digital rectal exam (DRE). The American Cancer Society recommends all men discuss screening with their healthcare provider at age 50, or earlier for high-risk groups.
Sources & References
American Cancer Society — “Prostate Cancer Statistics, 2025” (Kratzer et al., CA: A Cancer Journal for Clinicians, September 2025)
American Cancer Society — “Survival Rates for Prostate Cancer” (cancer.org, based on NCI SEER database 2015–2021)
National Cancer Institute (NCI) — SEER Cancer Stat Facts: Prostate Cancer (seer.cancer.gov)
American Cancer Society — Prostate Cancer Treatment Guidelines (cancer.org)
U.S. Preventive Services Task Force (USPSTF) — Prostate Cancer Screening Recommendations
Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions about a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read in this guide. If you or a loved one are dealing with prostate cancer, please consult with a board-certified oncologist for personalized medical guidance.